Momelotinib receives orphan drug status for rare VEXAS syndrome.

GSK's momelotinib, a JAK inhibitor, has been granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency. This designation supports the development of treatments for VEXAS syndrome, a severe and rare clonal myeloid disorder. The syndrome currently lacks approved therapies, making this status crucial for incentivizing research.